Updated June 2026 · USPTO PatentsView
When Does Pomalyst Patent Expire?
Pomalyst is protected by 3 US patents in the USPTO records tracked here. The earliest patent expires on Nov 19, 2030 (4.3 years from now), opening the door to potential generic or biosimilar competition for that specific composition. Full portfolio protection extends to Dec 21, 2031. Overall Patent Strength Score: 42/100 (Grade D, "weak").
Pomalyst Patent Snapshot
| Total US Patents | 3 |
| Earliest Patent Expiration | Nov 19, 2030 |
| Latest Patent Expiration | Dec 21, 2031 |
| Years Until First Expiry | 4.3 yr |
| Patent Holder | Celgene Corporation |
| Generic Name | pomalidomide |
| Patent Strength Score | D42/100 |
When the Pomalyst Patent Cliff Hits
Pomalyst's earliest patent expiration is in 2030, roughly 4.3 years out. That places this drug in the medium-term cliff window — most pharmaceutical analysts begin modeling generic erosion 3 to 5 years before the first composition-of-matter expiry, because that is when the FDA's 30-month stay clock starts ticking after the first ANDA filing. Latest portfolio expiration: 2031.
Because Pomalyst's earliest patent expiry is more than three years out, generic competition is not imminent. ANDA filings can occur as early as four years after NDA approval (the so-called "5-year exclusivity wall"), but actual market entry is gated by the latest unexpired patent. For clinicians and payers, the planning horizon for generic substitution on Pomalyst is 2030 at the earliest.
For the authoritative listing of patents tied to a specific drug — the patents an ANDA filer is legally required to address under 21 USC § 355(j) — consult the FDA Orange Book. Underlying utility patent data on this page is sourced from USPTO PatentsView, the federal government's free public patent API.
Inside the Pomalyst Patent Portfolio
Pomalyst is protected by 3 US patents — a compact portfolio. Compact portfolios are common for older drugs whose original composition patent has lapsed, leaving only formulation or method-of-use patents in force. They are also typical of newer drugs that have not yet accumulated the secondary patent layers (crystalline forms, dosing schedules, combination therapies) that build up over a successful product's lifecycle.
All 3 patents in the Pomalyst portfolio are assigned to Celgene Corporation, indicating consolidated ownership. Single-assignee portfolios are simpler to litigate and easier to license — generic challengers face one negotiating counterparty, and any settlement or pay-for-delay arrangement involves only that holder.
The Pomalyst portfolio scores 42/100 (Grade D, "weak") on the PatentCliff Strength index. The strongest signal is technology diversity (67/100), and the weakest is claims breadth (33/100). The four factors are weighted by how well they predict real-world resilience to generic challenge: portfolio size 30%, claims breadth 25%, time remaining 25%, and technology diversity 20%.
Earliest Patents in the Portfolio
| Patent # | Title | Expires | Years Left |
|---|---|---|---|
| 10555939 | Drug product (formulation / method-of-use) patent (incl. ped… | 2030 | 4.4 |
| 9993467 | Drug product (formulation / method-of-use) patent (incl. ped… | 2030 | 4.4 |
| 8828427 | Drug substance & product patent (incl. pediatric exclusivity… | 2031 | 5.5 |
Pomalyst vs Other Branded Drugs
Pomalyst's 3-patent portfolio is 63% smaller than the average drug tracked here (8 patents) — lighter-than-typical lifecycle protection. Among the 40 drugs in this database, Pomalyst ranks #17 by patent count. For broader context, the earliest expiration in the data set is Ozempic (2026) and the longest-protected drug is Mounjaro (latest expiry 2041).
Expiration Timeline
Looking at the 3 dated patents in the portfolio, the largest cluster (3 patents) falls in the "2–5 years (2029–2031)" bucket. That distribution matters because generic entry is gated by the latest unexpired blocking patent, not the earliest — even one late-expiring formulation patent can delay biosimilar launch by years if it survives a Paragraph IV challenge.
The 20-year patent term in the United States runs from the earliest non-provisional filing date, not the grant date. That means a patent granted in 2015 from a 2010 filing has only 15 years of life left at grant — a feature of US patent law that creates the layered "cliff" pattern visible in most branded drug portfolios. Patent Term Extension under 35 USC § 156 can add up to 5 years for time lost to FDA review, and pediatric exclusivity can add 6 months on top.
How the Patent Strength Score Is Calculated
The PatentCliff Strength Score combines four signals from USPTO data into a single 0-100 grade. Portfolio size (30%) measures the number of patents covering the drug — a proxy for litigation depth and the count of independent challenges a generic must clear. Claims breadth (25%) is the average number of claims per patent, an indicator of how broadly each patent attempts to cover the underlying invention. Time remaining (25%) measures average years until expiration across the portfolio. Technology diversity (20%) measures the number of distinct CPC (Cooperative Patent Classification) classes the portfolio touches — diverse portfolios are harder to design around. Read the full PatentCliff methodology, including how scores compare to citation-weighted academic measures.
Related Questions About Pomalyst
Sources: Patent records — USPTO PatentsView API (public domain). Drug-to-patent mapping cross-referenced against the FDA Orange Book. Expiration dates calculated as application date plus 20 years per 35 USC § 154.
Cite as: "PatentCliff, June 2026 reading. Source: USPTO PatentsView." Last updated 2026-06-24.
The data source behind this answer is the FDA Orange Book and USPTO patent records. Every figure on the page traces back to that source; the methodology page describes the inputs and the refresh cadence in full detail.
For readers turning this answer into action: cross-reference against the underlying the FDA Orange Book and USPTO patent records record before acting on time-sensitive decisions. The site renders the data as it was published; subsequent revisions can shift the picture, and the live federal data is always the authoritative current reference.